Paper Details
- Home
- Paper Details
Progresses Toward Precision Medicine in <i>RET</i>-altered Solid Tumors.
Author: AnandSantosh, AndrèFabrice, BelliCarmen, CuriglianoGiuseppe, DrilonAlexander, GainorJustin F, Penault-LlorcaFrederique, SubbiahVivek
Original Abstract of the Article :
<i>RET</i> (rearranged during transfection) gene encodes a receptor tyrosine kinase essential for many physiologic functions, but <i>RET</i> aberrations are involved in many pathologies. While <i>RET</i> loss-of-function mutations are associated with congenital disorders like Hirschsprung disease a...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1158/1078-0432.CCR-20-1587
データ提供:米国国立医学図書館(NLM)
Precision Medicine Takes Aim at RET-Altered Solid Tumors
Welcome, my fellow explorers, to the exciting frontier of precision medicine, where we're tackling cancer with a laser-like focus. This research highlights the importance of understanding the specific genetic mutations that drive tumor growth and the development of targeted therapies to combat them. The focus here is on RET, a gene that plays a vital role in cell signaling. When RET goes awry, it can contribute to the development of a range of cancers. The researchers delve into the intricacies of RET alterations, their impact on various cancers, and the development of targeted therapies to address these specific mutations.
Beyond Broad-Spectrum Therapies: The Rise of Targeted RET Inhibitors
Historically, cancer treatment has often relied on broad-spectrum therapies that target multiple pathways within the cell. However, these therapies are often accompanied by undesirable side effects. This research emphasizes the importance of developing targeted therapies that specifically address the genetic alterations driving a particular type of cancer. The development of selective RET inhibitors, like selpercatinib and pralsetinib, represents a significant advancement in precision medicine. These drugs are proving to be highly effective against RET-altered tumors, with fewer side effects and better response rates than traditional broad-spectrum treatments. The researchers meticulously examine the clinical features of RET-altered tumors, the specific genetic alterations involved, and the promising results of these targeted therapies.
A New Era of Personalized Cancer Treatment
This research paints a bright picture for the future of cancer treatment. The development of targeted therapies, such as RET inhibitors, signifies a shift towards a more personalized approach to medicine. By understanding the unique genetic profile of each patient's tumor, we can tailor treatment plans to maximize effectiveness and minimize adverse effects. This research underscores the importance of continued research and development in the field of precision medicine, as we strive to conquer cancer with greater precision and less collateral damage.
Dr.Camel's Conclusion
The quest for effective cancer treatments often feels like navigating a desert of uncertainty. This research offers a beacon of hope, revealing the immense potential of targeted therapies to address specific genetic alterations driving tumor growth. As we refine our understanding of these complex genetic pathways, we inch closer to a future where cancer treatment is more personalized and effective.
Date :
- Date Completed 2021-12-03
- Date Revised 2021-12-14
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.